glucose level News
-
Eversense NOW Remote Monitoring App for Android Users Receives CE Mark in Europe
Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it received CE mark of the Eversense® NOW Remote Monitoring App for the Android Operating System. The Eversense NOW iOS platform has previously been approved and ...
By Senseonics
-
Senseonics Announces Equity Grants To Employees Under Inducement Plan
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section ...
By Senseonics
-
Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01
Toronto, Canada, July 27, 2021 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first patients in its Phase 1b trial of ZT-01. “We are excited to advance ZT-01 to the next stage of development after our recent successful ...
-
Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01
Toronto, Canada, May 26, 2021 – Zucara Therapeutics Inc. (“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has successfully completed a Phase 1 study evaluating single and multiple ascending doses of ZT-01. “We are ...
-
Zucara Therapeutics Presents New Data at European Association for the Study of Diabetes
Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with Type 1 diabetes and other types of insulin-dependent diabetes, presented new findings today at the 55th Annual Meeting of the European Association for the Study of Diabetes on September 16-20, 2019 in Barcelona. The company recently undertook research to determine ...
-
Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes
Toronto, Canada, November 2, 2020 – Zucara Therapeutics Inc. (“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has expanded the development of ZT-01, a somatostatin receptor 2 antagonist (“SSTR2a”), to Type 2 ...
-
Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes
Zucara Therapeutics Inc. (“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has expanded the development of ZT-01, a somatostatin receptor 2 antagonist (“SSTR2a”), to Type 2 Diabetes (“T2D”). The ...
-
The EI Group Announces Wellness Partnership with North Carolina Medical Society
The North Carolina Medical Society Employee Benefit Plan (NCMS Plan) is excited to announce its new partner to conduct biometric screening for participating practices. As part of the Practice Wellness initiative, the NCMS Plan and the EI Group, Inc. (EI) will be working together to encourage medical practices to participate and adopt an effective and sustainable wellness culture with biometric ...
-
Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01
Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first subject in its Phase 1 trial of ZT-01. “Initiation of our Phase 1 study of ZT-01, which has been our goal since establishing the Company in 2014, is a monumental milestone for ...
-
Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01
Toronto, Canada, September 29, 2020 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first subject in its Phase 1 trial of ZT-01. “Initiation of our Phase 1 study of ZT-01, which has been our goal since establishing the ...
-
Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a stem cell-derived, fully differentiated pancreatic islet cell replacement therapy, have been accepted for presentation during the American Diabetes Association 82nd Annual Scientific ...
-
Human Factors And Usability Engineering - A `Must` Or A `Good To Have`? - Part 1
Human factors and usability are becoming more and more prevalent in the design and development process. So much so, that many organisations are placing a focus on the human factors element of their product development. But, is it a necessary inclusion or simply an added benefit? At eg technology, we live and breathe integrated end-to-end development. So, for us, the answer is simple. Human ...
-
Israeli Startup Wants to Cure Diabetes by Making Micro-pancreases. It Worked on Mice
Never mind better insulin shots or cell implants for diabetics: Betalin Therapeutics has a unique approach. A young Israeli company that has cured type-1 diabetes in mice and hopes to do the same for humans one day has won the MIXiii Biomed 2017 pharma startup competition, beating dozens of other firms. Just how cured were these mice, exactly? “They were cured of advanced stages of severe ...
-
Zucara Therapeutics Announces US$21 Million Series A Financing
Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has closed a US$21 million Series A Financing led by the Perceptive Xontogeny Venture Fund (“PXV Fund”). The proceeds from the financing will fund Phase 1 and Phase 2 clinical trials of ...
-
POGO Automatic One-Step™ Blood Glucose Monitor Now Available for People with Diabetes in the United States
Intuity Medical, Inc., a commercial-stage medical technology and digital health company focused on making life with diabetes easier, announced today the availability of the POGO Automatic Blood Glucose Monitoring System in the U.S. The product is the first and only FDA-cleared blood glucose monitor whose 10-test cartridge technology makes a glucose test possible with only the press of a button ...
-
Zucara Therapeutics Announces US$21 Million Series A Financing
Toronto, Canada, March 31, 2020 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has closed a US$21 million Series A Financing led by the Perceptive Xontogeny Venture Fund (“PXV Fund”). The proceeds from the financing will fund ...
-
Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
Clinical proof-of-concept achieved based on positive data from the first two patients dosed at half the target dose of cells in Part A of Phase 1/2 study First patient achieved insulin independence at Day 270; positive data in second patient; third patient has received full target dose with initiation of Part B VX-880 generally well tolerated in all three patients dosed to date ...
-
Innovative AI Technology Aids Personalized Care for Diabetes Patients Needing Complex Drug Treatment
Hitachi, Ltd. (TSE: 6501, Hitachi), University of Utah Health (U of U Health), and Regenstrief Institute, Inc. (Regenstrief) today announced the development of an AI method to improve care for patients with type 2 diabetes mellitus who need complex treatment. One in 10 adults worldwide have been diagnosed with type 2 diabetes, but a smaller number require multiple medications to control blood ...
-
FDA Approves Breath Test To Aid In Diagnosis Of Delayed Gastric Emptying
The U.S. Food and Drug Administration today approved the Gastric Emptying Breath Test (GEBT), a new non-invasive test to aid in the diagnosis of delayed gastric emptying, known as gastroparesis. Current tests used to diagnose gastroparesis typically involve the use of a small amount of radioactive material or imaging equipment, so testing must be conducted in specialized outpatient centers. ...
-
Inversago Pharma presents data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 59th Congress of the European Renal Association (ERA), the largest annual nephrology meeting in Europe, currently held in Paris, France. These data show that INV-202, the company’s lead peripheral CB1 ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you